On October 1, 2020, SPLIT and TTS co-hosted SPLIT’s 1st Virtual Annual Meeting with support and sponsorship from Astellas and Plexision. The meeting was a huge success! Over 400 participants from 6 continents and 20 countries participated. It was a true multi-disciplinary conference with representatives from hepatology, nephrology, cardiology, surgery, anesthesia, infectious diseases, intensive care, interventional radiology, rehabilitation, nursing and nutrition as well as transplant recipients and their family and friends. Excellent talks were delivered on timely topics in transplantation including COVID-19, transplant for small babies, ABO incompatible liver transplant, use of surveillance biopsies, sarcopenia, segmental graft use, acute liver failure and hepatopulmonary system (recordings of these talks as well as Session 2 Q and A responses are now available HERE). There was also a break-out educational session for current and upcoming transplant fellows to provide guidance on interviewing, mentorship and job opportunities. We look forward to SPLIT 2021.
Join WIT and ASHI for a virtual presentation by Dr. Lara Danziger-Isakov (Director, Immunocompromised Host Infectious Disease; Professor, UC Department of Pediatrics) on "Uneven Ground: Finding Your Feet during a Pandemic".
The event will be co-moderated by Dr. Elaine Reed (Woman Leader in Transplantation Award Winner 2020 and ex WIT Chair) and Dr. Roslyn Mannon (WIT Co-Chair).
You will receive an email to confirm that your interest has been registered and will receive precise details on how to access the event closer to the time.
J.H. Beigel et al.
NEJM. October 8, 2020, published at at NEJM.org. DOI: 10.1056/NEJMoa2007764
A preliminary version of this manuscript was published on May 22, 2020. A total of 1062 patients underwent randomization (with 541 assigned to remdesivir and 521 to placebo). Those who received remdesivir had a median recovery time of 10 days (95% confidence interval [CI], 9 to 11), as compared with 15 days (95% CI, 13 to 18) among those who received placebo (rate ratio for recovery, 1.29; 95% CI,1.12 to 1.49; P<0.001, by a log-rank test). The Kaplan–Meier estimates of mortality were 6.7% with remdesivir and 11.9% with placebo by day 15 and 11.4% with remdesivir and 15.2% with placebo by day 29 (hazard ratio, 0.73; 95% CI, 0.52 to 1.03).
Katherine A. Overmyer et al.
Cell Systems. October 5, 2020 DOI: https://doi.org/10.1016/j.cels.2020.10.003
This study performed RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities and outcomes. Quantified transcripts, proteins, metabolites, and lipids were associated with clinical outcomes in a curated relational database, uniquely enabling systems analysis and cross-ome correlations to molecules and patient prognoses. 219 molecular features with high significance to COVID-19 status and severity were mapped, many involved in complement activation, dysregulated lipid transport, and neutrophil activation. Sets of covarying molecules, e.g., protein gelsolin and metabolite citrate or plasmalogens and apolipoproteins, offering pathophysiological insights and therapeutic suggestions were identified. The observed dysregulation of platelet function, blood coagulation, acute phase response, and endotheliopathy further illuminated the unique COVID19 phenotype.
Researchers at McGill University are currently conducting a study entitled LIST-COVID-19 to study the impact of the COVID-19 pandemic on transplantation activity, volumes and immunosuppression practices on a global scale. The study will also help better understand the current and anticipated risks to transplantation during the pandemic and inform clinical practice during the “ramp-up” phase. The Transplantation Society is supporting the project, as well as several National and International Societies.
They are looking for physicians who take care of patients with a solid organ transplant to take a 10-15 minute survey on behalf of their center and program. Please note this is not a patient registry and no specific patient-level data is being collected. Please be assured they will only perform a collective analysis of the survey questions and no personal information identifying the participants will be divulged. The survey responses will be confidential. If you are interested in participating, please contact them at the emails listed below.
Investigators: Shaifali Sandal, MD and Marcelo Cantarovich, MD
The Transplantation Society (TTS) and our journal Transplantation have developed online resources to keep you informed on the Coronavirus (COVID-19) outbreak.
We are also requesting contributions and news from the transplant community to be sent to email@example.com for inclusion on our resources page.
In this dashboard, you will find links to TTS and other global and regional resources, as well as interactive maps, publications and webinars. We encourage you to explore this dashboard and share with your colleagues.
Editors and contributors to Transplantation have shared their thoughts on how they are dealing with the current crisis. While we understand that the information of today may be quite different tomorrow in this fast-moving pandemic, this report will open our forum of an international exchange on COVID for the transplant community.
Please send your own contributions and news to firstname.lastname@example.org for inclusion on our resources page.
Oct. 8 - After years of dedicated research, surgeons could be transplanting pig hearts into humans within the next year, according to a new analysis published in Circulation.
Oct. 8 - Researchers processed silk fibers into a versatile component of bioink for 3D cell printing technology. Printed objects retain their shape better than those produced without the silk additive, and the cells are not further damaged. This development will help advance regenerative medicine and drug discovery, and potentially reinvigorate the silk industry.
Oct. 6 - Fecal microbiota transplantation (FMT) is effective for Clostridium difficile infection (CDI) through six months and has a good safety profile, according to a study published online Oct. 1 in Gastroenterology.
Oct. 9 - Vanderbilt University Medical Center revealed that a COVID-19 patient was the recipient of a heart-lung transplant at the hospital, located in Nashville, Tennessee, on Sept. 24, 2020 - marking “the world’s first dual heart-lung transplant of a COVID-19 patient.”
The International Pancreas & Islet Transplant Association (IPITA) Conference Organizing Committee is committed to bringing the community together virtually.
TTS members are invited to attend the FOCIS 2020 Virtual Annual Meeting – THE meeting in translational immunology!
The Federation of Clinical Immunology Societies exists to improve human health through immunology.
The FOCIS 2020 Virtual Annual Meeting on October 28-31, 2020, brings together an interdisciplinary group of world-renowned physicians and researchers to share the latest findings on diseases impacting the immune system.